The Schall Law Firm is actively recruiting investors who purchased securities in Charming Medical Limited (NASDAQ: MCTA) during a three-week window in late 2025 to serve as lead plaintiffs in a proposed class action lawsuit alleging securities fraud. The recruitment effort targets shareholders who acquired MCTA stock between October 21 and November 12, 2025, a period preceding significant regulatory action against the company.
The lawsuit stems from an SEC trading suspension issued in November 2025, which followed investigations into an alleged undisclosed promotion scheme. According to regulatory findings, social media advisors promoted the stock without adequate disclosure or legitimate business justification, raising questions about the integrity of trading information available to retail investors during the period in question. The suspension halted trading in MCTA securities amid the agency's inquiry into potential market manipulation.
Investors who meet the eligibility criteria and experienced losses during the specified timeframe are being encouraged to participate in the litigation. Lead plaintiffs typically represent the interests of the broader investor class and may receive compensation for their role in advancing the case. The Schall Law Firm will manage the legal proceedings, which seek to recover damages on behalf of affected shareholders.